NASDAQ:STOK
Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc.'s revenue grew 404.5% in fiscal 2025 to $184.4M while operating margin rose to −11.2%, its highest in 4 years. Free cash flow was $44.9M, 24.4% of revenue, and the diluted share count rose 9.6%.Summary generated from Stoke Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$184.4M
Revenue growth+404.5%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−11.2%
Net margin−3.7%
ROICn/a
Return on equity−2.4%
Debt / equityn/a
Free cash flow$44.9M
FCF margin24.4%
Share count change+9.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | 12 | 9 | 37 | 184 |
| Operating income | −86 | −104 | −115 | −101 | −21 |
| Net income | −86 | −101 | −105 | −89 | −7 |
| Free cash flow | −68 | −36 | −83 | −87 | 45 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Oct 2, 2026 - 8-KDirector or officer change
Sep 25, 2026 - 8-KOther events
Aug 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 3, 2026 - 8-KResults of operations and financial condition
Aug 3, 2026 - 8-KRegulation FD disclosure
Jun 30, 2026 - 8-KResults of a shareholder vote
Jun 4, 2026